Denali Therapeutics IncNASDAQ:DNLI
- LAST PRICE21.1400
- TODAY'S CHANGE (%)-0.1600 (-0.7512%)
- Bid / Lots18.5800/ 10
- Ask / Lots23.5000/ 1
- Open / Previous Close21.0600 / 21.3000
- Day Range
- 52 Week Range
- Volume471,281
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DNLI |
|---|---|---|
| 09:32 ET | 14877 | 21.02 |
| 09:34 ET | 300 | 21 |
| 09:36 ET | 482 | 21.09 |
| 09:38 ET | 900 | 20.845 |
| 09:39 ET | 14000 | 20.97 |
| 09:41 ET | 800 | 21.07 |
| 09:43 ET | 1263 | 21.085 |
| 09:45 ET | 1778 | 21.26 |
| 09:48 ET | 600 | 21.12 |
| 09:50 ET | 800 | 21.13 |
| 09:52 ET | 1066 | 21.095 |
| 09:54 ET | 400 | 21.08 |
| 09:56 ET | 1400 | 21.1 |
| 09:57 ET | 1100 | 21.14 |
| 09:59 ET | 200 | 21.19 |
| 10:01 ET | 3613 | 21.15 |
| 10:03 ET | 400 | 21.09 |
| 10:06 ET | 1124 | 21.1 |
| 10:08 ET | 300 | 21.11 |
| 10:10 ET | 100 | 21.09 |
| 10:12 ET | 100 | 21.1 |
| 10:14 ET | 28300 | 21.09 |
| 10:15 ET | 1100 | 21.125 |
| 10:17 ET | 1551 | 21.09 |
| 10:19 ET | 300 | 21.09 |
| 10:21 ET | 100 | 21.07 |
| 10:24 ET | 1300 | 21.09 |
| 10:26 ET | 100 | 21.07 |
| 10:28 ET | 512 | 21.07 |
| 10:30 ET | 200 | 21.07 |
| 10:32 ET | 1281 | 21.0759 |
| 10:33 ET | 551 | 21.13 |
| 10:35 ET | 1200 | 21.08 |
| 10:37 ET | 700 | 21.1 |
| 10:39 ET | 2444 | 21.145 |
| 10:42 ET | 100 | 21.14 |
| 10:44 ET | 300 | 21.16 |
| 10:46 ET | 555 | 21.13 |
| 10:48 ET | 100 | 21.13 |
| 10:50 ET | 400 | 21.19 |
| 10:51 ET | 1500 | 21.17 |
| 10:53 ET | 400 | 21.175 |
| 10:55 ET | 700 | 21.205 |
| 10:57 ET | 100 | 21.19 |
| 11:00 ET | 600 | 21.155 |
| 11:02 ET | 100 | 21.12 |
| 11:04 ET | 200 | 21.14 |
| 11:06 ET | 400 | 21.17 |
| 11:08 ET | 1300 | 21.16 |
| 11:11 ET | 1300 | 21.185 |
| 11:13 ET | 300 | 21.22 |
| 11:15 ET | 2897 | 21.24 |
| 11:18 ET | 200 | 21.24 |
| 11:20 ET | 100 | 21.24 |
| 11:22 ET | 100 | 21.25 |
| 11:26 ET | 500 | 21.205 |
| 11:27 ET | 500 | 21.2 |
| 11:29 ET | 3200 | 21.175 |
| 11:31 ET | 4177 | 21.16 |
| 11:33 ET | 1699 | 21.135 |
| 11:36 ET | 600 | 21.205 |
| 11:38 ET | 300 | 21.195 |
| 11:40 ET | 244 | 21.22 |
| 11:44 ET | 100 | 21.23 |
| 11:45 ET | 100 | 21.28 |
| 11:47 ET | 200 | 21.29 |
| 11:49 ET | 400 | 21.28 |
| 11:51 ET | 865 | 21.28 |
| 11:54 ET | 600 | 21.29 |
| 11:56 ET | 300 | 21.27 |
| 11:58 ET | 903 | 21.2 |
| 12:00 ET | 500 | 21.18 |
| 12:02 ET | 1185 | 21.17 |
| 12:03 ET | 100 | 21.16 |
| 12:05 ET | 745 | 21.17 |
| 12:07 ET | 300 | 21.18 |
| 12:09 ET | 1087 | 21.17 |
| 12:12 ET | 405 | 21.2123 |
| 12:14 ET | 400 | 21.17 |
| 12:16 ET | 203 | 21.185 |
| 12:18 ET | 300 | 21.18 |
| 12:20 ET | 1100 | 21.21 |
| 12:21 ET | 200 | 21.19 |
| 12:23 ET | 100 | 21.21 |
| 12:25 ET | 100 | 21.19 |
| 12:27 ET | 1700 | 21.16 |
| 12:30 ET | 300 | 21.195 |
| 12:32 ET | 784 | 21.16 |
| 12:34 ET | 500 | 21.16 |
| 12:36 ET | 927 | 21.175 |
| 12:38 ET | 200 | 21.17 |
| 12:39 ET | 350 | 21.16 |
| 12:41 ET | 1146 | 21.14 |
| 12:43 ET | 300 | 21.12 |
| 12:45 ET | 300 | 21.1 |
| 12:48 ET | 300 | 21.09 |
| 12:50 ET | 100 | 21.09 |
| 12:52 ET | 100 | 21.09 |
| 12:54 ET | 200 | 21.06 |
| 12:57 ET | 200 | 21.06 |
| 12:59 ET | 700 | 21.06 |
| 01:01 ET | 400 | 21.03 |
| 01:03 ET | 790 | 21.06 |
| 01:06 ET | 800 | 21.05 |
| 01:08 ET | 200 | 21.05 |
| 01:10 ET | 503 | 21.07 |
| 01:12 ET | 900 | 21.07 |
| 01:14 ET | 200 | 21.065 |
| 01:15 ET | 100 | 21.05 |
| 01:17 ET | 100 | 21.04 |
| 01:19 ET | 424 | 21.04 |
| 01:21 ET | 100 | 21.03 |
| 01:24 ET | 700 | 21.07 |
| 01:28 ET | 1253 | 21.07 |
| 01:30 ET | 100 | 21.09 |
| 01:32 ET | 200 | 21.08 |
| 01:35 ET | 600 | 21.1 |
| 01:37 ET | 3772 | 21.095 |
| 01:39 ET | 318 | 21.09 |
| 01:42 ET | 637 | 21.09 |
| 01:44 ET | 1100 | 21.12 |
| 01:46 ET | 500 | 21.11 |
| 01:48 ET | 300 | 21.09 |
| 01:50 ET | 200 | 21.08 |
| 01:51 ET | 300 | 21.1 |
| 01:53 ET | 1006 | 21.125 |
| 01:55 ET | 100 | 21.11 |
| 01:57 ET | 200 | 21.125 |
| 02:00 ET | 300 | 21.13 |
| 02:02 ET | 400 | 21.13 |
| 02:04 ET | 200 | 21.13 |
| 02:06 ET | 200 | 21.13 |
| 02:08 ET | 500 | 21.1 |
| 02:09 ET | 900 | 21.09 |
| 02:11 ET | 953 | 21.071 |
| 02:13 ET | 4558 | 21.01 |
| 02:15 ET | 200 | 21.01 |
| 02:18 ET | 300 | 20.99 |
| 02:20 ET | 3912 | 21.025 |
| 02:22 ET | 627 | 21.02 |
| 02:24 ET | 480 | 21.02 |
| 02:26 ET | 100 | 21.035 |
| 02:29 ET | 100 | 21.05 |
| 02:31 ET | 500 | 21.02 |
| 02:33 ET | 100 | 21.02 |
| 02:36 ET | 1707 | 21.03 |
| 02:38 ET | 100 | 21.02 |
| 02:40 ET | 4908 | 21.05 |
| 02:42 ET | 1284 | 21.065 |
| 02:44 ET | 200 | 21.08 |
| 02:45 ET | 600 | 21.06 |
| 02:47 ET | 300 | 21.06 |
| 02:49 ET | 700 | 21.03 |
| 02:51 ET | 200 | 21.07 |
| 02:56 ET | 200 | 21.07 |
| 02:58 ET | 200 | 21.07 |
| 03:00 ET | 700 | 21.07 |
| 03:02 ET | 400 | 21.06 |
| 03:03 ET | 100 | 21.07 |
| 03:05 ET | 250 | 21.1097 |
| 03:07 ET | 1300 | 21.16 |
| 03:09 ET | 1611 | 21.23 |
| 03:12 ET | 1333 | 21.22 |
| 03:14 ET | 1911 | 21.18 |
| 03:16 ET | 200 | 21.2 |
| 03:18 ET | 4126 | 21.131 |
| 03:20 ET | 300 | 21.13 |
| 03:21 ET | 100 | 21.145 |
| 03:23 ET | 400 | 21.16 |
| 03:25 ET | 300 | 21.165 |
| 03:27 ET | 880 | 21.14 |
| 03:30 ET | 200 | 21.14 |
| 03:32 ET | 400 | 21.17 |
| 03:34 ET | 1866 | 21.16 |
| 03:36 ET | 1500 | 21.16 |
| 03:38 ET | 1000 | 21.18 |
| 03:39 ET | 900 | 21.185 |
| 03:41 ET | 1187 | 21.21 |
| 03:43 ET | 700 | 21.21 |
| 03:45 ET | 1818 | 21.2 |
| 03:48 ET | 600 | 21.19 |
| 03:50 ET | 1138 | 21.215 |
| 03:52 ET | 3029 | 21.21 |
| 03:54 ET | 1941 | 21.185 |
| 03:56 ET | 4737 | 21.18 |
| 03:57 ET | 3911 | 21.15 |
| 03:59 ET | 19648 | 21.14 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Denali Therapeutics Inc | 3.0B | -21.9x | --- |
MorphoSys AG | 2.8B | -5.5x | --- |
Amicus Therapeutics Inc | 3.0B | -20.3x | --- |
Arrowhead Pharmaceuticals Inc | 3.2B | -6.0x | --- |
Genmab A/S | 16.8B | 21.2x | +22.71% |
TG Therapeutics Inc | 2.9B | 86.2x | --- |
Company Information
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).
Contact Information
- Headquarters
- 161 Oyster Point BlvdSOUTH SAN FRANCISCO, CA, United States 94080-1910
- Phone
- 650-866-8548
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Vicki Sato
- President, Chief Executive Officer, Director
- Ryan Watts
- Chief Financial Officer, Chief Operating Officer, Company Secretary
- Alexander Schuth
- Chief Medical Officer
- Carole Ho
- Director
- Steven Krognes
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.0B |
|---|---|
Revenue (TTM) | $295.4M |
Shares Outstanding | 142.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.39 |
EPS | $-0.97 |
Book Value | $7.45 |
P/E Ratio | -21.9x |
Price/Sales (TTM) | 10.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -65.54% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
